Strategic cooperation丨PackGene and Pall work together to create the future of gene therapy
On February 23, 2021, PackGene and Pall Co., Ltd. signed a strategic cooperation agreement. The two parties have carried out close cooperation on large-scale AAV production based on gene therapy, empowered the process platform, and jointly provided more efficient...
PackGene received B+ round of financing led by Sequoia China and co-invested by Decheng Capital
In October 2020, PackGene Biotech, Inc. (PackGene), an integrated solution provider focusing on AAV vector packaging and gene therapy CDMO, announced the completion of a new round of B+ round of financing, which was led by Sequoia China, followed by Decheng Capital....
PackGene received tens of millions of B round investment from Cathay Capital and Oriza Seed—help to accelerate the upgrading of Chinese gene therapy industry
Core Reminder: In August 2020, PackGene Biotech, Inc. ("PackGene"), a well-known provider of integrated CDMO solutions and AAV vector packaging for gene therapy, announced the completion of the B round of tens of millions yuan in financing. In August 2020, PackGene...
Nature Communications & Nature Neuroscience | PackGene helps the cutting-edge AAV-based researches development
1. PackGene AAV helped the research of using AAVR to identify different mechanisms of AAV serotypes Adeno-associated virus (adeno-associated virus, AAV) belongs to the Parvoviridae dependent virus genus. It has the advantages of good safety, wide tropism, can infect...
PackGene Biotech has completed tens of millions of A round of financing-to promote the industrialization of gene therapy
A round of financing In February 2020, PackGene Biotech, Inc. (hereinafter referred to as "PackGene") completed the A round of financing invested by Tengye Ventures. In the future, PackGene will continue to promote the technological innovation of viral vectors,...